Literature DB >> 25075097

Multicolor analysis of cell surface marker of human leukemia cell lines using flow cytometry.

Tomoko Inoue1, Anthony Swain2, Yoichi Nakanishi3, Daisuke Sugiyama1.   

Abstract

BACKGROUND: Leukemia cell lines are utilized as tools for molecular analysis. Their implementation in therapy will require standards for quality control, including appropriate selection criteria for functional analysis and efficacy determination.
MATERIALS AND METHODS: Characteristics of six human leukemia cell lines -Kasumi-1, NB-4, MOLM-13, MV-4-11, K562, and Jurkat cells-were investigated using multiple color analysis of surface antigen expression and comparative analysis of gene expression.
RESULTS: Differentiation states of Kasumi-1 and MOLM-13 cells are colony-forming units-granulocyte/macrophage equivalent cells to myeloblasts with comparatively high Growth factor independent-1(GFI1) and Transcription factor PU.1 (PU.1) expression, respectively. NB4 and MV-4-11 express high levels of CCAAT/enhancer-binding protein-alpha (CEBPα) and differentiate from myeloblasts to pro-monocytes and myeloblasts, respectively. K562 cells are colony-forming units-erythroid equivalent cells to erythroblasts, with the highest expression of GATA-binding factor 2 (GATA2), GATA1 and Friend of gata-1 (FOG1). Jurkat cells are pro-T to mature T-cells with the highest Neurogenic locus notch-1 homolog protein 1 (NOTCH1) expression.
CONCLUSION: Our study gives a useful guideline of standards for appropriate usage of leukemia cell lines for examining novel targets in vitro. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Leukemia cell line; cell surface marker; flow cytometry

Mesh:

Substances:

Year:  2014        PMID: 25075097

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Elongation Index as a Sensitive Measure of Cell Deformation in High-Throughput Microfluidic Systems.

Authors:  Scott J Hymel; Hongzhi Lan; Damir B Khismatullin
Journal:  Biophys J       Date:  2020-07-07       Impact factor: 4.033

2.  Programmable Assembly of Adeno-Associated Virus-Antibody Composites for Receptor-Mediated Gene Delivery.

Authors:  Alina C Zdechlik; Yungui He; Eric J Aird; Wendy R Gordon; Daniel Schmidt
Journal:  Bioconjug Chem       Date:  2019-12-20       Impact factor: 4.774

3.  Actin Polymerization Is Required for Filopodia Formation Supporting HSV-1 Entry into Activated T Cells.

Authors:  Thanayod Sasivimolrattana; Pokrath Hansasuta; Supang Maneesri Le Grand; Parvapan Bhattarakosol
Journal:  Curr Microbiol       Date:  2021-12-14       Impact factor: 2.188

4.  SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes.

Authors:  Yen K Lieu; Zhaoqi Liu; Abdullah M Ali; Xin Wei; Alex Penson; Jian Zhang; Xiuli An; Raul Rabadan; Azra Raza; James L Manley; Siddhartha Mukherjee
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-04       Impact factor: 12.779

5.  Sulfurtransferases and Cystathionine Beta-Synthase Expression in Different Human Leukemia Cell Lines.

Authors:  Halina Jurkowska; Maria Wróbel; Ewa Jasek-Gajda; Leszek Rydz
Journal:  Biomolecules       Date:  2022-01-18

6.  In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features.

Authors:  Ignazia Tusa; Giulia Cheloni; Martina Poteti; Angela Silvano; Alessandro Tubita; Zoe Lombardi; Antonella Gozzini; Roberto Caporale; Barbara Scappini; Persio Dello Sbarba; Elisabetta Rovida
Journal:  Target Oncol       Date:  2020-10       Impact factor: 4.493

7.  Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia.

Authors:  Margaret Am Nelson; Kelsey L McLaughlin; James T Hagen; Hannah S Coalson; Cameron Schmidt; Miki Kassai; Kimberly A Kew; Joseph M McClung; P Darrell Neufer; Patricia Brophy; Nasreen A Vohra; Darla Liles; Myles C Cabot; Kelsey H Fisher-Wellman
Journal:  Elife       Date:  2021-06-16       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.